VERU INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
VERU INC. (VERU) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 16.90 million shares for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2023-08-10
- VERU INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-06-30 was 16.90M shares.
- VERU INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2020-12-31 was 1.40M shares.
- VERU INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2015-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- VERU INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2014-12-31 was 276.15K shares, a 13.38% decline year-over-year.
- VERU INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 1.20M shares.
- VERU INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2017 was 2.70M shares.
- VERU INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2014 was 342.86K shares, a 2.00% decline from fiscal 2013.
- VERU INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2013 was 349.87K shares, a 71.77% decline from fiscal 2012.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|
| 2023-06-30 | 16.90M shares 10-Q · filed 2023-08-10 | |||||
| 2021-09-30 | 1.20M shares 10-K · filed 2022-12-05 | |||||
| 2021-06-30 | 819.00K shares 10-Q · filed 2022-08-11 | |||||
| 2021-03-31 | 211.00K shares 10-Q · filed 2022-05-12 | |||||
| 2020-12-31 | 1.40M shares 10-Q · filed 2022-02-09 | |||||
| 2017-09-30 | 2.70M shares 10-K · filed 2018-01-02 | |||||
| 2015-06-30 | 0.00 shares 10-Q · filed 2015-07-30 | 0.00 shares 10-Q · filed 2015-07-30 | ||||
| 2014-12-31 | 276.15K shares 10-Q · filed 2015-02-03 | |||||
| 2014-09-30 | 342.86K shares 10-K · filed 2014-12-02 | |||||
| 2014-06-30 | 323.78K shares 10-Q · filed 2014-07-31 | 337.54K shares 10-Q · filed 2014-07-31 | ||||
| 2014-03-31 | 0.00 shares 10-Q · filed 2015-04-30 | 353.13K shares 10-Q · filed 2014-05-01 | 0.00 shares 10-Q · filed 2015-04-30 | 361.76K shares 10-Q · filed 2014-05-01 | ||
| 2013-12-31 | 318.80K shares 10-Q · filed 2015-02-03 | |||||
| 2013-09-30 | 349.87K shares 10-K · filed 2014-12-02 | |||||
| 2013-06-30 | 368.76K shares 10-Q · filed 2014-07-31 | 358.35K shares 10-Q · filed 2014-07-31 | ||||
| 2013-03-31 | 364.35K shares 10-Q · filed 2014-05-01 | 362.96K shares 10-Q · filed 2014-05-01 | ||||
| 2012-12-31 | 361.54K shares 10-Q · filed 2014-02-03 | |||||
| 2012-09-30 | 1.24M shares 10-K · filed 2014-12-02 | |||||
| 2012-06-30 | 1.55M shares 10-Q · filed 2013-08-01 | 1.49M shares 10-Q · filed 2013-08-01 | ||||
| 2011-09-30 | 1.68M shares 10-K · filed 2013-12-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |